EVALUATION OF SERUM LEVEL OF ANTI-MÜLLERIAN HORMONE IN PRE-ECLAMPSIA

<p style="text-align: justify;">Pre-eclampsia is a multiorgan disease process characterized by hypertension and proteinuria after 20 weeks of gestation. The aim of the study was to assess the serum level of anti-Müllerian hormone (AMH) in pregnant women as a predictor for pre-eclampsia. A case control study was carried out in Baghdad Teaching Hospital from 2020 to 2021. A sample of 192 pregnant women in the third trimester participated in the study and were divided into two main groups. The first group enrolled 96 normotensive pregnant women (control group), and the second group included 96 patients with pre-eclampsia (as a case group). The latter group was subdivided into 36 patients with mild to moderate pre-eclampsia, and 60 with severe pre eclampsia. Blood samples were taken from each woman (case and control group) to test the AMH level, liver function tests, renal function tests, serum uric acid, serum lactate dehydrogenase (LDH), and complete blood picture. Urine samples were analyzed for albumin concentration and spot urine was assessed for protein-to-creatinine ratio. Anti-Müllerian hormone levels were significantly lower in the case group than in the control group (p < 0.001). In the control group, the AMH level was 4.92 ± 1.79 ng/ml, while for mild to moderate pre-eclampsia group, it was 1.56 ± 0.21 ng/ml, and 0.42 ± 0.38 ng/ml for severe pre-eclampsia. Systolic and diastolic blood pressure showed significant higher values in the case group (p < 0.001). Gestational age, serum uric acid and serum albumin had moderate correlation with AMH in pre-eclampsia with significant association. The level of AMH was decreased significantly in pregnant women with pre-eclampsia in comparison to healthy<br /> pregnancy.</p>